摘要
目的观察滋肾丸含药血清对脂多糖(LPS)刺激的大鼠膀胱平滑肌细胞表达Toll样受体4(TLR4)、Toll样受体5(TLR5)及其下游信号转导通路髓样分化蛋白(MyD88),以及MYD88非依赖型途径激活核因子-κB(NF-κB)蛋白表达的影响。方法用LPS(1μg/m L)刺激大鼠膀胱平滑肌细胞株,同时分别给予滋肾丸含药血清5.54、27.7 g/(kg.U)进行干预,Western-blot方法测定TLR4,TLR5和下游通路相关蛋白的表达,分析评价滋肾丸含药血清的现代药效学基础。结果滋肾丸含药血清27.7 g/(kg.U)对LPS刺激的TLR4、TLR5及其下游通路的MyD88和NF-κB有抑制作用,滋肾丸含药血清5.54 g/(kg.U)对LPS刺激的病理性升高无抑制作用。结论滋肾丸的药效学作用可能与抑制TLR4、TLR、MyD88和NF-κB蛋白表达有关,且与剂量呈依赖性。
Objective To observe the influences of Zishen Wan to bladder smooth muscle cells in rats on the expression of TLR4, TLR5 and the factors of the downstream in Lipopolysaccharide （LPS） stimulation of bladder smooth muscle cells in rats. Methods Bladder smooth muscle cell line was stimulated with Lipopolysaccharide, and treated with the drug serum of Zishen Wan 5.54,27.7g/ （kg·U） simultaneously. Measured the expression of TLR4, TLR5 and other correlated indexes of the downstream, analyzed and evaluated Zishen Wan＇s substance basis of pharmacodynamic actions. Results Zishen Wan 27.7 g/（kg·U） serum depressed the expression ofTLR4, TLR5, MyD88 and NF-κB protein, but Zishen Wan drug 5.54g/（kg·U） serum had no effects on pathological elevated. Conclusion Depressing the expression of TLR4, TLR5, MyD88 and NF-κB protein may be the elementary basis ofZishen Wan＇s pharmacodynamic actions. And that its dose dependent relationship.
出处
《长春中医药大学学报》
2017年第2期212-214,共3页
Journal of Changchun University of Chinese Medicine
基金
江苏省苏州市科技局科研立项"基于TLR4/MyD88信号通路探讨滋肾丸治疗尿路感染的黏膜免疫机制"(SYS201421)
